- Home
- SLS vs BCSF Comparison
SLS vs BCSF Comparison
Compare SLS & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLS | BCSF |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.7M | 818.0M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SLS | BCSF |
|---|---|---|
| Price | $5.92 | $12.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 5.5M | 591.4K |
| Earning Date | 04-16-2026 | 05-20-2026 |
| Dividend Yield | N/A | ★ 15.40% |
| EPS Growth | ★ 62.69 | N/A |
| EPS | N/A | ★ 1.53 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.31 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $12.43 |
| 52 Week High | $5.66 | $17.42 |
Technical Indicators
Market Signals| Indicator | SLS | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 74.63 | 38.58 |
| Support Level | $1.48 | $12.49 |
| Resistance Level | N/A | $14.53 |
| Average True Range (ATR) | 0.50 | 0.43 |
| MACD | 0.13 | -0.05 |
| Stochastic Oscillator | 93.19 | 15.07 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.